Table II.

Immunologic outcome of colonic exposure to limiting doses of SIVmac239 and SIV/17E-Fr

Expt.SIV CloneMonkeySeruma Ab TiterLPb ELISPOTCTLc
3 wk p.i.8 wk p.i.
PBMCLPMLNPBMCLPMLN
ISIVmac239N25506env [5]env [4]
M22451,2000
M02900pol [12]env [8]NDNDND
L87000env [39]env [29]
SIV/17E-FrL98700
M25900gag [5]
M57700env [57]env [42]env [8]
IISIV/17E-FrN0410NTdNTNTNTenv [22]NT
N3853200NTNTNTNTenv [33]env [17]NT
gag [50]gag [36]
N1383200NTNTNTNTNT
M1550NTNTNTNTNT
  • a Reciprocal dilution; gp120-specific.

  • b Max. No. SIV-specific IgA+ cells/750,000 total lymphocytes.

  • c Target specificity of SIV gag, pol, and env targets tested (15% LU/106 CD8+cells).

  • d NT, not tested.